Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies-Reference-Cited by-同舟云学术

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

Published:2020-01 Issue:1 Volume:95 Page:77-89
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Wright R. Scott,Collins Michael G.^ORCID,Stoekenbroek Robert M.,Robson Richard,Wijngaard Peter L.J.,Landmesser Ulf,Leiter Lawrence A.,Kastelein John J.P.,Ray Kausik K.,Kallend David

Funder

Baxter Healthcare Pty Ltd

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Heart disease and stroke statistics—2019 update: a report from the American Heart Association;Benjamin;Circulation,2019

2. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories;Foreman;Lancet,2018

3. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;J Am Coll Cardiol,2014

4. A century of cholesterol and coronaries: from plaques to genes to statins;Goldstein;Cell,2015

5. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials;Cholesterol Treatment Trialists’ (CTT) Collaborators;Lancet,2012

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database;International Journal of Clinical Pharmacy;2024-08-27

2. Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024;BMC Nephrology;2024-07-06

3. Inclisiran: the preclinical discovery and development of a novel therapy for the treatment of atherosclerosis;Expert Opinion on Drug Discovery;2024-05-28

4. Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis;Frontiers in Pharmacology;2024-05-17

5. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups;Expert Opinion on Drug Safety;2024-05-07